Meet us at
Anxiofit Ltd. develops dietary supplements against anxiety and improving emotional well-being based on scientific evidence.
We devoted years of scientific research and carried out several clinical studies to provide support for the growing number of people occasionally experiencing anxiety, stress, nervous inner tension, and restless sleep.
The company’s first preparation, EP107™, has been successfully marketed for more than 8 years under AnxioCalm brand in the US.
The main component of EP107™ is an ancient herb Echinacea. Echinacea is traditionally used for immune support for the respiratory track, but a group of Hungarian scientists found that a unique type of narrow leaved Echinacea from selected growing areas has proven anxiolytic effects in small dose. Precise standardization ensures a characteristic alkamide profile, making such an effect clinically measurable. Beside its effective anxiolytic effect, EP107™ does not have sedative side effects as most existing preparations do.
Anxiolytic effects of certain herbs and compounds are researced funded by EU grants, with a special emphasis to the endocannabinoid system, CB1 and CB2 receptors. This led to the invention that active principles of certain kind of Echinacea has anxiolytic effects. The effect highly depends on the type of plant, where it is grown, which part of the plant is used and how it is processed.
Sources for the echinacea supply have been screened. Only few could supply raw materials in stable quality.
Scientific methods have been developed to ensure that the final products always have the right quantity of active ingredients (alkamides) responsible for the anxiolytic effect, as some ingredients in Echinacea might even increase anxiety.
Together with a GMP certified pharma manufacturer (Extractum Pharma) the EP107™ dietary supplement tablet was developed and production started of the 20mg EP107™ minipills.
4 animal and 4 human clinical trials have been completed to prove that EP107™ - without side effects -, is ameliorating sub-threshold and mild anxiety, which are clear risk factors in development of anxiety disorders and depression. Articles are published and patents have been filled.
In 2010 the first tablets were sold in the US market (under the AnxioCalm brand by Europharma Inc).
In 2016 the AnxioCalm product received licenses with new healthclaims for distribution also in Canada.
In 2021 new vegan formulation was developed for the EU markets. The distribution of the same new tablets started under different local brands like Cannanx (Austria), AnxioFree (Slovenia) and AnxioControl (Hungary and Turkey).
Meet the Team
Prof. Tamás F. Freund
Chairman of the Board
Chairman of the Neuroscience Department, P. Pazmany Catholic University. He has been President of the Federation of European Neuroscience Societies and he is the President of the Hungarian Academy of Sciences.
He was an Executive Committee Member and Head of Business Development at Affidea Group one of the fastest growing healthcare service groups in Europe and an early investor and President of Oncompass Medicine
He founded the Behavioral Neurobiology Department of the Institute of Experimental Medicine, Budapest. He obtained the Doctor in Science degree at the Hungarian Academy of Science (2004) in behavioral neurobiology.
After some years in the packaging industry, she has dedicated most of her professional life to build up the worldwide distributor network for dietary supplements and medical devices of different brands.
Prof. Jozsef Haller
Head of Sales
The small tablets of Anxiofit are based on EP107™, a special blend of Echinacea extracts gathered from selected growing areas with a unique profile of active principles.
The unique EP107™ ingredient is patent protected, fast acting, and non-sedative.
In small quantity EP107™ decreases sub-threshold and mild anxiety, which are well known risk factors of serious anxiety disorders and depression.
Proprietary analytics on all ingredient batches ensure that the special alkamides (active principles) responsible for the anxiolytic effect are present in the right proportion and alkamides that are potentially increasing anxiety are absent.
Upon request reports of clinical trials are available, showing the anxiolytic effect of the products. The outcome measures used to assess this effect were the State-Trait Anxiety Inventory by Spielberger.
AnxioFit original, 120 mg coated tablets manufactured in Hungary in pharma quality. Tablets contain 20mg EP107™.
Vegan diatery supplement tablets, without lactose and talc and with 40mg EP107™.
Vegan dietary supplement tablets, with 40mg EP107™, Vitamin B6 and Matricaria Recutita.
The AnxioCalm dietary supplements in the US & Canada are targeting the large population of people experiencing occasional anxiety, not receiving conventional medical treatment and favouring side effect free herbal medications, which has scientifically described mechanism of action and a measurable effect.
Our tablets containing EP107™ were launched under different brand names in Austria, Slovenia, Hungary and Turkey. We are looking forward to enter new markets! Professional, marketing and communication material is available for those who prefer to take final/branded products. In case of interest for distribution, please contact us!